Roche (ROP SW) Q1 2026 (CHF): Sales 14.72bln (prev. 15.44bln Y/Y), Group Sales +6% at constant exchange rates, -5% in CHF, due to significant currency appreciation; confirms 2026 outlook

Sales by Region:

• US: 5.69bln (prev. 6.22bln Y/Y)
• Europe: 2.23bln (prev. 2.32bln Y/Y)
• Japan: 649mln (prev. 671mln Y/Y)

Sales by Unit:

• Group: driven by high demand for our innovative medicines and diagnostics.
• Pharmaceutical: +7% at CER, -4% in CHF, +10% in USD. Due to continued high growth in sales of medicines for the treatment of severe diseases: Xolair, Phesgo, Hemlibra, Vabysmo & Ocrevus were the top drivers.
• Diagnostics: +3% at CER, -7% in CHF, +7% in USD. Demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China.

2026 Outlook: 

• Confirmed.
• Core EPS in the high single-digit range at CER.
• Expects to increase dividend in CHF.